Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 320-329

  Wang, Xiaoming ^a   Vernikovskaya, Daria I ^a   Abdelrahman, Doaa R ^a   Hankins, Gary D V ^a   Ahmed, Mahmoud S ^a   Nanovskaya, Tatiana N ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

BUP; Bupropion; EB; ESI; LC MS MS; LLOQ; LOD; Metabolites; MRM; MS; OH BUP; Placenta; S N; TB; TCA; Umbilical cord plasma

Indexed keywords

ACETONITRILE; AMFEBUTAMONE; DEUTERIUM; DRUG METABOLITE; ERYTHROHYDROBUPROPION; FORMIC ACID; METHANOL; RADAFAXINE; THREOBUPROPION; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG;

ACCURACY; ACIDIFICATION; AQUEOUS SOLUTION; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; DRUG METABOLISM; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIMIT OF QUANTITATION; MASS SPECTROMETRY; PLACENTA; PRECIPITATION; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

ACETONITRILES; BIOTRANSFORMATION; BUFFERS; BUPROPION; CALIBRATION; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; FETAL BLOOD; FORMATES; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYLATION; LIMIT OF DETECTION; LINEAR MODELS; METHANOL; PLACENTA; PREGNANCY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SMOKING CESSATION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84866248910     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.05.008     Document Type: Article

References (25)

1. Benowitz N.L., Dempsey D.A. Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob. Res. 2004, 6:S189-S202.
2. U.S. Department of Health and Human Services. The Health Benefits of Smoking Cessation: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990.
3. Fang W.L., Goldstein A.O., Butzen A.Y., Hartsock A., Hartmann K.E., Helton M., Lohr J.A. Smoking cessation in pregnancy: a review of postpartum relapse prevention strategies. J. Am. Board Fam. Pract. 2004, 17:264-275.
4. Gilman S.E., Breslau J., Subramanian S.V., Hitsman B., Koenen K.C. Social factors, psychopathology, and maternal smoking during pregnancy. Am. J. Public Health 2008, 98:448-453.
5. Schneider S., Maul H., Freerksen N., Pötschke-Langer M. Who smokes during pregnancy? An analysis of the German Perinatal Quality Survey 2005. Public Health 2008, 122:1210-1216.
6. Windsor R., Oncken C., Henningfield J., Hartmann K., Edwards N. Behavioral and pharmacological treatment methods for pregnant smokers: issues for clinical practice. J. Am. Med. Womens Assoc. 2000, 55:304-310.
7. Fiore M.C., Jaén C.R., Baker T.B., Bailey W.C., Benowitz N.L., Curry S.J., Dorfman S.F., Froelicher E.S., Goldstein M.G., Healton C.G., Henderson P.N., Heyman R.B., Koh H.K., Kottke T.E., Lando H.A., Mecklenburg R.E., Mermelstein R.J., Mullen P.D., Orleans C.T., Robinson L., Stitzer M.L., Tommasello A.C., Villejo L., Wewers M.E., Murray E.W., Bennett G., Heishman S., Husten C., Morgan G., Williams C., Christiansen B.A., Piper M.E., Hasselblad V., Fraser D., Theobald W., Connell M., Leitzke C. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. May 2008, U.S. Department of Health and Human Services. Public Health Service, Rockville, MD.
8. Schroeder D.H. Metabolism and kinetics of bupropion. J. Clin. Psychiatry 1981, 44:79-81.
9. Earhart A.D., Patrikeeva S., Wang X., Abdelrahman D.R., Hankins G.D., Ahmed M.S., Nanovskaya T. Transplacental transfer and metabolism of bupropion. J. Matern. Fetal Neonatal. Med. 2010, 23:409-416.
10. Wang X.M., Abdelrahman D.R., Zharikova O.L., Patrikeeva S.L., Hankins G.D., Ahmed M.S., Nanovskaya T.N. Bupropion metabolism by human placenta. Biochem. Pharmacol. 2010, 79:1684-1690.
11. Parekh J.M., Sutariya D.K., Vaghela R.N., Sanyal M., Yadav M., Shrivastav P.S. Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxylbupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. Biomed. Chromatogr. 2011, 26:314-326.
12. Yeniceli D., Dogrukol-A.K. An LC Method for the determination of bupropion and its main metabolite, hydroxybupropion in human plasma. Chromatographia 2009, 780:1703-1708.
13. Zhang D., Yuan B., Qiao M., Li F. HPLC determination and pharmacokinetics of sustained-release bupropion tablets in dogs. J. Pharm. Biomed. Anal. 2003, 33:287-293.
14. Coles R., Kharasch E. Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. J. Chromatogr. B 2007, 857:67-75.
15. Xu H., Loboz K., Gross A., Mclachlan A.J. Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality 2007, 19:163-170.
16. Borges V., Yang E., Dunn J., Henion J. High-throughput liquid chromatography-tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column. J. Chromatogr. B 2004, 804:277-287.
17. Cooper T.B., Suchow R.F., Glassman A. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J. Pharm. Sci. 1984, 73:1104-1107.
18. Loboz K.K., Gross A.S., Ray J., McLachlan A.J. HPLC assay for bupropion and its metabolites in human plasma. J. Chromatogr. B 2005, 823:115-121.
19. Denooz O., Mercerolle M., Lachatre G., Charlier C. Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of bupropion and its main metabolites in human whole blood. J. Anal. Toxicol. 2010, 34:280-286.
20. FDA, Guidance for Industry, Bio-analytical Method Validation, Food and Drug Administration, Centre for Drug Evaluation and Research, May 2011; http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm123635.htm.
21. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Workshop/Conference Report-Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand biding assays. AAPS J. 2007, 9:E30-E42.
22. Yeniceli D., Sener E., Korkmaz O.T., Dogrukol-Ak D., Tuncel N. A simple and sensitive LC-ESI-MS (ion-trap) method for the determination of bupropion and its metabolite, hydroxyburpopion in rat plasma and brain microdialysates. Talanta 2011, 84:19-26.
23. Cheng C., Liu S., Xiao D., Hanel S. The application of trichloroacetic acid as an ion pairing reagent in LC-MS-MS method development for highly polar aminoglycoside compounds. Chromatographia 2010, 72:133-139.
24. Loco J.V., Elskens M., Croux C., Beernaert H. Linearity of calibration curves: use and misuse of the correlation coefficient. Accred. Qual. Assur. 2002, 7:281-285.
25. Laizure S.C., Vane C.L.D. Stability of bupropion and its major metabolites in human plasma. Ther. Drug Monit. 1985, 7:447-450.